Patent ID: 11885817
Assignee: COGNIZANCE BIOMARKERS, LLC
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC C  G

Claim 5:
6. A method of treating epilepsy in a patient in need of epilepsy treatment, the method comprising:
contacting one or more blood samples obtained from the patient with one or more antibodies targeting one or more biomarkers selected from the group consisting of interleukin-16 (IL-16), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), tumor necrosis factor (TNF)-α, IL-5, tumor necrosis factor-beta (TNF-β), MCP-1, interleukin-10 (IL-10), MIP-1a, IL-12/IL-23p40, IL-17A, stem cell factor (SCF), IL-1a, macrophage derived chemokine (MDC), TNF-RII, Eotaxin-3, interferon-gamma (IFN-γ), IL-13, IL-2, IL-4, and IL-6;
measuring the concentrations of the one or more biomarkers in the one or more blood samples; comparing the concentrations of the one or more biomarkers in the one or more blood samples to the concentration of the one or more biomarkers in one or more controls; and
treating the patient for epilepsy by administering to the patient one or more therapeutic agents selected from the group consisting of phenytoin, carbamazepine, oxcarbazepine, zonisamide, lamotrigine, and pharmaceutically acceptable salts and prodrugs thereof;
wherein the patient is in need of epilepsy treatment when the concentrations of the one or more biomarkers are decreased in the one or more blood samples relative to the one or more controls.